The gene-editing technology known as CRISPR has attracted much excitement and investor interest with its potential to someday treat diseases by fixing faulty copies of genes. But recently, a different approach called RNA editing, which could offer advantages over CRISPR, has been gaining ground in academic labs and start-ups, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
RNA editing uses an enzyme called ADAR to make precise edits to RNA, the shorter-lived cousin to DNA that acts as a blueprint for proteins. Researchers direct ADAR to specific RNAs with a guide sequence attached to the enzyme. Unlike CRISPR gene editing, the effects of RNA editing are reversible because cells are constantly making new copies of RNA. Therefore, RNA editing avoids the risks of permanent gene editing with CRISPR, writes Assistant Editor Ryan Cross, and could also be used to treat temporary conditions, such as pain or inflammation.
However, finding an easy way to control how ADAR makes its edits has been challenging. Researchers have tried chemically attaching ADAR to a guide RNA, adding an RNA-binding protein or even linking the catalytic portion of ADAR to the bacterial Cas9 enzyme used in CRISPR. However, these approaches require getting the modified enzymes into human cells. Some researchers are working on using human cells’ own ADAR for RNA editing, by introducing chemically modified guide RNAs that recruit the editing enzyme and direct it to specific RNAs. With researchers and investors becoming increasingly interested in this approach, RNA editing could someday give CRISPR a run for its money, Cross writes.
The article, “Watch out, CRISPR. The RNA editing race is on,” is freely available here.
Learn more: Interest in RNA editing heats up
The Latest on: RNA editing
[google_news title=”” keyword=”RNA editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: RNA editing
- Novel genetic mechanisms may serve as therapeutic target against gliomaon May 17, 2024 at 7:36 am
A study from the laboratory of Shi-Yuan Cheng, Ph.D., professor in the Ken and Ruth Davee Department of Neurology's Division of Neuro-oncology, has identified novel mechanisms underlying RNA splicing ...
- How Gene Editing Therapies Could Go Beyond Rare Diseaseson May 16, 2024 at 6:00 am
In the wake of the first CRISPR medicine, scientists are working to develop gene editing therapies for diseases like cystic fibrosis, ALS and cardiovascular disease.
- Korro Bio Earns Buy Rating from Analyst Mitchell Kapoor on Groundbreaking RNA Editing Technology and Strong Preclinical Resultson May 15, 2024 at 3:28 am
Korro Bio (KRRO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor ...
- Buy Rating on Wave Life Sciences: Promising Pipeline and Market Potentialon May 15, 2024 at 3:12 am
Tiago Fauth, an analyst from Wells Fargo, has initiated a new Buy rating on Wave Life Sciences (WVE). Tiago Fauth has given his Buy rating due ...
- Researchers complete mitochondrial genome analysis of endangered plant Primulina hunanensison May 13, 2024 at 9:06 am
Primulina hunanensis is a perennial herb in the genus Primulina Hance of the family Gesneriaceae. It is very adaptable to low-light and barren cave environments, and is unique in its species evolution ...
- Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brainon May 8, 2024 at 6:32 am
RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA delivery RNAfix achieves >95% editing throughout the mouse brain with sustained durability at least 6 months ...
- Scientists' research on RNA editing illuminates possible lifesaving treatments for genetic diseaseson April 28, 2024 at 5:00 pm
DNA editing uses a CRISPR-associated protein called Cas9, while editing RNA requires the use of a different CRISPR system, called type-III. "In our previous work, we used type-III CRISPRs to edit ...
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingon April 22, 2024 at 6:31 am
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer “Editing ...
- Kinetoplastids and Their Networks of Interlocked DNAon November 16, 2021 at 6:40 pm
By studying this amazing structure, how did scientists learn about RNA editing? The first tools developed for the study of cells and tissues were optical microscopes. These microscopes use visible ...
- 2nd RNA Editing Summit 2020on October 4, 2020 at 5:00 pm
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible.
via Bing News